


Catalog # 10-2379

Terazosin HCl

63074-08-8

1-(4-Amino-6,7-dimethoxy-2-quinazolinyl-4-[(tetrahydro-2-furanyl)carbonyl]piperazine

Lot # X106805



α_1 - and α_{2B} -adrenoceptor antagonist (K_i = 3.3, 0.7, 1.1, 7.7, 1510 and 78.2 nM for α_{1A} , α_{1B} , α_{1D} , α_{2B} , α_{2A} and α_{2C} receptors respectively)¹. Displays antihypertensive activity². Improves glucose and lipid metabolism in hypertensives³. Displays antiangiogenic activity in human prostate cancer and endothelial cells⁴. Activates Pgk1 and Hsp90 to promote stress resistance⁵. Active *in vivo*.

- 1) Hancock *et al.* (1995), *Actions of terazosin and its enantiomers at subtypes of alpha-1 and alpha-2 adrenoceptors in vitro*; Recept. Signal Transduct. Res., **15** 863
- 2) Kyncl *et al.* (1986), *Pharmacology of terazosin*; Am. J. Med., **80** 12
- 3) Shionoiri *et al.* (1994), *Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study*; Am. J. Med. Sci., **307 Suppl 1** S91
- 4) Pan *et al.* (2003), *Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells*; J. Urol., **169** 724
- 5) Chen *et al.* (2015), *Terazosin activates Pgk1 and HSP90 to promote stress resistance*; Nat. Chem. Biol., **11** 19

PHYSICAL DATA

Molecular Weight:	423.88
Molecular Formula:	C ₁₉ H ₂₅ N ₅ O ₄
Purity:	98% by HPLC
	NMR: (Conforms)
Solubility:	Water (up to 20 mg/ml with warming)
Physical Description:	White solid
Storage and Stability:	Store as supplied desiccated at -20°C for up to 2 years from the date of purchase. Solutions in distilled water may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.